U.S. Bioservices will pay $13.4 million to settle a lawsuit concerning allegations the company illegally billed federal and state insurers for prescriptions for Novartis AG’s Exjade in exchange for referrals from the drugmaker, according to a filing from the U.S. Attorney’s Office.
Source: Drug Industry Daily